Lupin - U.S. FDA Regulatory Hurdle Crossed At Goa: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
After almost 4.5 years of regulatory hurdles, Lupin Ltd. received a favorable classification (Voluntary Action Indicated) for its Goa facility from the U.S. Food and Drug Administration.
This is a big relief from a compliance standpoint, given the reasonable contribution in the base business as well as double digit abbreviated new drug applications pending approval from the Goa site.
We expect 21% earnings compound annual growth rate over FY21-23E and raise our 12-month forward price/earning to 25 times (to factor Goa compliance) from 24 times earlier.
While the regulatory clearance removes a key overhang on Goa facility, we maintain our stance on Lupin as valuation leaves limited upside from current levels.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.